Clinical trials: Lipemia
Primary Prevention
ProSALUTE: Community Program for Cardiovascular Health
The purpose of this study is to determine the efficacy and cost/effectiveness (change in CV risk factors and lifestyle vs costs) of ProSALUTE as a new organizational model of primary CV prevention.
- Trial name
- ProSALUTE (NCT03129165)
- Testing
- Screening and prevention of CVD
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Centro Cardiologico Monzino
Hypercholesterolemia
Long Term Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols and Berberine) in Low-moderate Risk Hypercholesterolemic Patients: a Double-blind, Placebo Controlled Study
Background: Statins are at the forefront of strategies to manage hypercholesterolemia. However, 10-15% of patients result to be intolerant to any statins, even at low daily doses and almost one- third of statin users discontinue…
- Trial name
- NCT02078167
- Testing
- nutraceutical combination (red yeast rice, policosanols and berberine)
- Volunteers
- 60 people
- Sponsor
- Comitato Etico di Area Vasta Sud Est
Graves' Ophthalmopathy, Hypercholesterolemia
Graves' Orbitopathy and Hypercholesterolemia
The investigators have recently observed retrospectively that the occurrence of Graves' Orbitopathy in patients with Graves' disease is less frequent in patients with normal cholesterol levels, in line with another recent…
- Trial name
- GOCol (NCT02721992)
- Testing
- No intervention
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- University of Pisa
Hypercholesterolemia
Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia
IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R…
- Trial name
- NCT03815812
- Testing
- IBI306
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
HIV Infections, Hyperlipidemia
Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients
open-label, multiple dose, single-group, 12 week trial in HIV-infected patients with hyperlipidemia while using lopinavir/ritonavir; both male or female subjects.
- Trial name
- NCT00184951
- Testing
- Rosuvastatin
- Where
- 5 sites in Germany, Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Hypercholesterolemia
Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
CKJX839D12304 was a research study to determine if the study treatment, called inclisiran, in comparison to placebo and ezetimibe effectively reduces Low-Density Lipoprotein Cholesterol (LDL-C) as measured by percentage change…
- Trial name
- V-Mono (NCT05763875)
- Testing
- Inclisiran, Ezetimibe
- Where
- 42 sites in United States, Colombia and 3 more
- Volunteers
- 350 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Familial, Lipid Metabolism, Inborn Errors
Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)
The purpose of this study is to provide an investigational drug to patients with a specific type of hypercholesterolemia (high cholesterol) or sitosterolemia (unusually high absorption of non-cholesterol sterols) in a treatment…
- Trial name
- NCT00092833
- Testing
- Comparator: ezetimibe
- Volunteers
- 49 people
- Sponsor
- Organon and Co
Dyslipidemias, Hypercholesterolemia
Cholesterol-lowering Effects of Plant Stanol Ester
Efficacy of plant stanols as esters on LDL-cholesterol reduction is well documented. LDL-cholesterol lowering efficacy of the ingredient administered in a smoothie is less well known.
- Conditions
- Dyslipidemias, Hypercholesterolemia, Hyperlipidemias
- Trial name
- NCT02316808
- Testing
- Plant stanol ester
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Raisio Group
Hyperlipidemias, Hypercholesterolemia
Supplementation of Oil Palm Phenolics to Improve Lipid Profile in Subjects With Minor Hyperlipidaemia
An unpublished study by the investigators on healthy participants has shown that the supplementation of oil palm phenolics (OPP) at 250 mg is the optimum dose to demonstrate the ability to lower total and LDL cholesterol.
- Trial name
- NCT04573218
- Testing
- 250 mg OPP
- Where
- Malaysia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Isa Naina Mohamed
Cardiovascular Diseases, Hypercholesterolemia
Magnetic Resonance Imaging-Portfolio Diet Study #7
Presently in Canada, 29% of deaths are due to cardiovascular disease (CVD), costing $20.9 billion annually. The investigators have, therefore, brought together an unique network of investigators at different stages in their…
- Conditions
- Cardiovascular Diseases, Hypercholesterolemia, Diabetes, Metabolic Syndrome
- Trial name
- MRIPD#7 (NCT02078635)
- Testing
- Portfolio Plus Diet, DASH-like (high fibre) dietary advice
- Where
- 4 sites in Canada
- Sponsor
- Unity Health Toronto
HIV Infections, Hypercholesterolemia
Garlic in Hyperlipidemia Caused by HAART
The purpose of this study is to test the effectiveness and tolerability of garlic pills in lowering cholesterol and triglycerides in hyperlipidemic HIV-infected individuals who are being treated with highly active antiretroviral…
- Conditions
- HIV Infections, Hypercholesterolemia, Hypertriglyceridemia, Hyperglycemia
- Trial name
- NCT00029250
- Testing
- Garlic powder standardized to allicin
- Where
- 2 sites in United States
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Renal Failure Chronic Requiring Hemodialysis, Metabolic Syndrome
Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients
Hyperlipidemia and atherosclerosis lead to cardiovascular diseases and are an indirect cause of increased death rate in the general population.
- Conditions
- Renal Failure Chronic Requiring Hemodialysis, Metabolic Syndrome, Diabetes Mellitus Type 2, Hyperlipidemia
- Trial name
- NCT01448174
- Testing
- Atorvastatin
- Where
- Poland
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Poznan University of Medical Sciences
Subjects With Hyperlipidemia, Dyslipidemia
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
A study to assess the effects of proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibition on the arterial wall inflammation in patients with elevated lipoprotein(a).
- Trial name
- ANITSCHKOW (NCT02729025)
- Testing
- Evolocumab
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 129 people
- Sponsor
- Amgen
Statins, HMG-CoA, Single Nucleotide Polymorphism
Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, also known as statins, played an important role in lipid-lowering therapy and reduction of cardiovascular risks.
- Trial name
- NCT00509574
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Hyperlipidemia
Effect of Cheese on Cardiovascular Risk
The main objective of the current study is to examine whether a high intake of regular-fat cheeses (Danbo and Cheddar) affect blood lipids differently than an isocaloric intake of either other fatty animal food products or of…
- Trial name
- ECCA (NCT01739153)
- Testing
- Dietary intervention: CHEESE (High cheese intake), Dietary intervention: MEAT (High Meat intake), Dietary intervention: CARB (High Carbohydrate intake)
- Where
- Denmark
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Hypercholesterolemia
A Comparison of the Effects on Cardiovascular Risk Factors of Korean and American Dietary Profiles
The primary aim of this study is to compare, in a group of at-risk individuals, the role of three dietary patterns on indices of Cardiovascular Disease (CVD) risk: a) the recommended Korean pattern; b) the typical American diet…
- Trial name
- NCT01617525
- Testing
- Controlled Feeding Dietary Intervention
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- USDA Beltsville Human Nutrition Research Center
Atherosclerotic Cardiovascular Disease
VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging…
- Trial name
- V-INCLUSION (NCT06249165)
- Testing
- Inclisiran
- Where
- 23 sites in United States
- Volunteers
- 130 people
- Sponsor
- Duke University
Hypercholesterolemia
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)
This study will evaluate the effects of 2 different dose levels of anacetrapib on low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) in participants with hypercholesterolemia when added…
- Trial name
- NCT01717300
- Testing
- Anacetrapib 100 mg, Anacetrapib 25 mg
- Volunteers
- 459 people
- Sponsor
- Merck Sharp & Dohme LLC
Familial Hypercholesterolemia
A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication
This study is designed to assess whether colesevelam given as third line treatment added to a maximal tolerated and stable dose of a statin and ezetimibe is able to further decrease the level of LDL cholesterol in a safe and…
- Trial name
- NCT00655265
- Testing
- Colesevelam hydrochloride film-coated tablets
- Where
- 8 sites in France, Germany and 3 more
- Volunteers
- 86 people
- Sponsor
- Genzyme, a Sanofi Company
Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Heart Disease (CHD)
VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN)
The goal of this study is to understand and compare an alternative model of care in comparison to the usual model of care in include male and female participants ≥18 years of age with a history of ASCVD (hear and blood vessels…
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Heart Disease (CHD), Cerebrovascular Disease, Peripheral Arterial Disease (PAD)
- Trial name
- v-ASCERTAIN (NCT05834673)
- Testing
- SMS messages, Telephone-based support calls, GP Education
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Monash University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.